Intelence Receives New FDA Approval
FDA approves new 200 mg tablet for HIV/AIDS medication
Intelence, a medication taken by HIV/AIDS patients, has just been approved for a new 200 mg tablet, a move that will help lessen the number of pills which need to be taken daily.
The Food and Drug Administration approved a new 200 mg Intelence (etravirine) tablet. Intelence was originally approved in 2008, in only a 100 mg tablet formulation. The new 200 mg dosage form can help reduce pill burden for patients taking Intelence.
The dosage Dosage and Administration section was changed to state: 200 mg (one 200 mg or two 100 mg tablets) taken twice daily following a meal.
Intelence is a nonnucleoside reverse transcriptase inhibitors (NNRTI), made by Tibotec Therapeutics.
The revised product label, reflecting the 200 mg tablet approval can be found at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022187s007lbl.pdf
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.
More health news
Prescription DrugsFDA Approves Intelence
Medication approved for pediatric HIV patients
FDA AlertsFDA Expands Label for Daklinza
Daclatasvir label expanded to include hepatitis C genotype 1, 3 infection by FDA
FDA AlertsFDA Approves New HIV Drug
FDA approves Viramune XR for treating HIV-1 infection